Cutting-Edge Heart Failure Research and Innovations Coming to Boston, March 2-4
NEW YORK – February 24, 2026 – The full lineup of late-breaking clinical science to be presented at THT 2026: Technology and Heart Failure Therapeutics is available online. Organized by the Cardiovascular Research Foundation® (CRF®), this premier international heart failure conference will be held March 2-4, at the Omni Boston Hotel at the Seaport in Boston, MA.
Celebrating its fifth year, THT has become a leading international forum dedicated to advancing cutting-edge treatments for heart failure. THT 2026 will spotlight the latest breakthroughs in device-based, technology-driven, and pharmacologic therapies aimed at improving outcomes and reshaping the future of cardiovascular care. Developed by a distinguished faculty of program directors, this year’s meeting will feature first-time presentations of clinical trial results, in-depth discussions on key research topics, and insights into emerging innovations..
The program includes three dedicated sessions with 24 late-breaking clinical science presentations, each exploring new transcatheter and interventional strategies for the management of heart failure patients.
Late-Breaking Clinical Science I
Monday, March 2, 2026
2:00 PM — 3:20 PM EST
Ensemble A-B | Level 2
Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial
Amish Raval
Initial Six-Month Outcomes With Baroreflex Activation Therapy From the REBALANCE Registry
Dmitry Yaranov
Prospective Validation of the STOPSHOCK Score for Early Cardiogenic Shock Prediction in Acute Coronary Syndrome: A Real-World Perspective
Allan Böhm
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and the Risk of Heart Failure Hospitalizations in Patients With Chronic Heart Failure
Michael R. Zile
Effect of Cardiac Contractility Modulation (CCM) Therapy on Reverse Remodeling in Heart Failure Patients with Left Ventricular Ejection Fraction 25-45%
Rami Kahwash
Disentangling The Central, Peripheral And Hematological Mechanisms Of Benefit Of Sotatercept On Exercise Performance In Pulmonary Arterial Hypertension
Yogesh Reddy
Predicted vs. Observed 3-Year Mortality in the ALT FLOW Early Feasibility Study Cohort
Javed Butler
HeartCon: Pioneering VAD Development in China
Xiaocheng Liu
Late-Breaking Clinical Science II
Tuesday, March 3, 2026
8:00 AM — 9:30 AM EST
Ensemble A-B | Level 2
Prognostic Value of NT-proBNP in Patients Undergoing Tricuspid Valve Transcatheter Edge-to-Edge Repair: The EuroTR Registry
Jennifer von Stein
Artificial Intelligence Meets Real-World Heart Failure: Early Results from the HF-TRACK Trial
Teresa Castiello
Feasibility and Safety of Clinician-Directed Patient Self-Management of Congestion Using an Implantable Inferior Vena Cava Sensor
Nir Uriel
Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock – A Secondary Analysis of the DanGer Shock Trial
Elric Zweck
Left Atrial To Coronary Sinus Shunting In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 3-Year Results
Benjamin Hibbert
Optimal Mean Arterial Pressure, Time in Target Range, and Outcomes in HeartMate 3 Recipients: Pooled Individual-Patient Data from MOMENTUM-3 and ARIES-HM3 Trials
Nelson Wang
Incidence of HF Therapy Escalation and Time-to-Clinical Worsening in Atrial Shunt- vs. Sham-Treated Patients with HFpEF/HFmrEF During 5-Year Follow-Up: REDUCE LAP-HF II Trial
Grant Reed
Early Cardiac Contractility Modulation (CCM) Therapy Use Reduces Heart Failure-Related Hospitalization
Daniel Burkhoff
Medication Regimen Changes and Clinical Outcomes in the Cardiac Microcurrent (C-MIC) II Randomized Trial
Marat Fudim
Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes from the REDUCE LAP-HF II Trial
Sanjiv J. Shah
Late-Breaking Clinical Science III
Wednesday, March 4, 2026
8:00 AM — 9:00 AM EST
Ensemble C-D | Level 2
The Highly Dynamic Nature Of Diuretic Response In Acute Heart Failure: Insights From The FASTR Trial
Zachary L. Cox
Impella-Bridge Strategy Tended To Be Associated With Lower Mortality Following Durable Left Ventricular Assist Device Implantation In Japan
Makiko Nakamura
The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials
Beth A. Davison
Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era
Francis D. Pagani
Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial
Sheldon E. Litwin
Beyond Survival: Defining Success After Total Artificial Heart Implantation
Andre Simon
Additional information on THT is available at https://tht2025.crfconferences.com/.
